News

The Phase I trial, which is being conducted in the US, is designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of TC-5214 in healthy volunteers. TC-5214 is

Revenue for the year ended December 31, 2007 was $18.1 million, compared to $28.5 million for the year ended December 31, 2006. Net loss for the three months

This new initiative will focus on accessing large clinical cohorts for validating its diagnostic products through the company’s collaborative network. Lipomics will use its analytical and bioinformatic technology

This approval is conditional upon the company’s submission of additional information to the FDA over the next 45 days. The AMI shock study will determine the safety and

These stents are indicated for use in the palliative treatment of malignant strictures in the biliary tree that can restrict the flow of digestive fluids and compromise digestion.

The warrants have a seven year term and an exercise price of $2.77 per share. The transaction is expected to raise approximately $25.3 million in gross proceeds. The

Avance Nerve Graft is said to be the only off-the-shelf product available that gives surgeons the option to repair damaged peripheral nerves with human allograft nerve. Avance Nerve

The financing was led by Saad Investments Company and included Masa Life Science Ventures of Washington, District of Columbia and private investors. Eric Adams, president and CEO of

The Phase IIb trial is a US multi-center, randomized, parallel, open-label study in 278 treatment-naive, genotype 1 patients evaluating taribavirin at 20mg/kg, 25mg/kg, and 30mg/kg per day in